“The investigational program for asedebart demonstrates Lundbeck’s commitment to deepen our efforts in rare diseases and endocrinological conditions with links to brain function. This program also illustrates our approach to directly target underlying disease biology. As one of our focus markets, we are especially pleased to receive ODD for asedebart in Japan and the opportunity this provides to address significant unmet needs for people living with CAH and CD,” says Johan Luthman, EVP and Head of R&D, Lundbeck